Is the Exclusion of Patients With Left Ventricular Diastolic Dysfunction Limiting the Trials?

The study excluded patients with left ventricular diastolic dysfunction. Can you outline why this exclusion was considered a portant? And then as a second dairy follow-up question, do you think in being so stringent as to exclude based on risk factors rather than the presence of actual disease that this limits the trials overall generalizability? Yeah, great question. I'd maybe step back and mention that there's been this interesting shift in demographics of pulmonary arterial hypertension over time with an increasing age of the time of diagnosis.